The 2015-2016 emergence of Zika virus (ZIKV) in the Americas, and recognition that ZIKV 15 infection during pregnancy can result in birth defects, revealed a need for small animal models to 16 study ZIKV pathogenic mechanisms and evaluate candidate vaccines and antivirals. Mice would 17 be an attractive system for such studies, but ZIKV replicates poorly in laboratory mice because it 18 fails to antagonize murine STAT2 and STING. To address this, most ZIKV pathogenesis studies 19 have used mice with impaired interferon signaling (e.g. Ifnar1 -/or treatment with IFNAR1-blocking 20 antibodies). However, using mice with severe defects in innate antiviral signaling confounds 21 studies of viral pathogenic mechanisms. Collaborative Cross (CC) mice have proven to be a 22 valuable system for developing new mouse pathogenesis models for viral infections that are not 23 well modeled in conventional laboratory mouse lines. To test whether CC mice could provide an 24 immune-competent model for ZIKV pathogenesis, we infected CC lines with ZIKV and assessed 25 weight loss, viremia, and production of neutralizing antibodies. We tested 21 CC lines (CC001, 26
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The 2015-2016 emergence of Zika virus (ZIKV) in the Americas, and recognition that ZIKV 39 infection during pregnancy can result in birth defects, revealed a need for small animal models to 40 study ZIKV pathogenic mechanisms and evaluate candidate vaccines and antivirals (1). Mice 41 would be an attractive system for such studies due their low cost and genetic tractability and mice 42 have proven to be a valuable system for studying other flaviviruses, such as West Nile virus 43 (WNV). However, studies of ZIKV in mice are confounded because mouse type I interferon (IFN-44 αβ) signaling restricts ZIKV replication (2), in part due to the inability of ZIKV to antagonize murine 45 STAT2 and STING (3) (4) (5) (6) . This results in diminished ZIKV replication in immune competent mice 46 and has led most groups to use IFN-deficient mouse models including mice lacking the type I 47 and/or type II IFN receptors (e.g., Ifnar1 -/or Ifnar1 -/-Ifngr1 -/double knockout), mice with defects 48 in IFN induction or signaling (e.g., Irf3 -/-Irf5 -/-Irf7 -/or Stat2 -/-), or mice treated with IFNAR1-49 blocking antibody (7) . These models are useful because they allow robust ZIKV replication and 50 produce severe disease outcomes with high penetrance. However, these models have significant 51 limitations for studying immune mechanisms that control ZIKV replication and disease. In 52 particular, IFN signaling plays a key role in restricting flavivirus tropism and IFN-deficient mice 53 typically develop disseminated ZIKV infection that does not recapitulate the tissue tropism 54 observed in humans. Thus, there is a need for new mouse models that exhibit robust ZIKV 55 replication and disease within an immune competent host. 56
57
The Collaborative Cross (CC) is a mouse genetic reference population that was developed to 58 study complex trait genetics and to model genetically complex populations, such as humans (8, 59 9) . CC mice are derived from eight founder lines: five founder lines are classical laboratory lines 60
with an extensive history of use in mouse genetics, microbial pathogenesis, and disease models 61 (C57BL/6J, 129S1/SvImJ, A/J, NOD/ShiLtJ, and NZO/HiLtJ). The other three CC founder lines 62 are wild-derived inbred lines, which represent the three major subspecies of Mus musculus: 63 casteneus (CAST/EiJ), musculus (PWK/PhJ), and domesticus (WSB/EiJ), and introduce much of 64 the genetic diversity into the CC. These eight founder strains were interbred in a funnel breeding 65 scheme to produce recombinant mice with genomic contributions from each founder, which were 66 then bred to homozygosity to produce approximately 80 recombinant inbred CC lines. The CC 67 mouse genetic reference population is designed to model the genetic diversity present in human 68 populations and allow the identification and study of polymorphic host genes underlying complex 69 phenotypes, including the immune response to viral infection. Because each CC line is inbred, 70 they provide a reproducible system to study diverse phenotypes. 71
72
The genetic architecture of the CC results in a broad spectrum of antiviral responses, including 73 responses not observed in standard mouse lines that more closely resemble the clinical outcomes 74 observed in humans (8, 9) . This has resulted in the development of mouse models for pathogens, 75 such as Ebola virus, severe acute respiratory syndrome (SARS) coronavirus, WNV, and 76 chikungunya virus, that better model clinical aspects of human disease compared to standard 77 laboratory mouse lines (10-12). Therefore, we sought to use the CC to identify polymorphic host genes that control ZIKV specific innate and adaptive immunity and determine whether variation 79 in these genes impacts ZIKV susceptibility. These experiments would have the potential to identify 80 CC lines with enhanced susceptibility to ZIKV replication and disease, thereby resulting in the 81 the viral E protein (14-17). ZIKV strain Dakar-MA was generated by serially passaging strain 102
Dakar 41525 in Rag1 -/mice to generate a mouse-adapted variant and was provided by Dr. 103 and titered by focus-forming assay (FFA) (18). Duplicates of serial 10-fold dilutions of virus in viral 105 growth medium (DMEM containing 2% FBS and 20 mM HEPES) were applied to Vero cells in 96-106 well plates and incubated at 37 o C with 5% CO 2 for 1 hr. Cells were then overlaid with 1% 107 methylcellulose in minimum essential medium Eagle (MEM). Infected cell foci were detected 42-108 46 hpi. Following fixation with 2% paraformaldehyde for 1 hr at room temperate, plates were 109 incubated with 500 ng/ml of flavivirus cross-reactive mouse MAb E60 (19) for 2 hr at room 110 temperature or overnight at 4 o C. After incubation at room temperate for 2 hr with a 1:5,000 dilution identify polymorphic host genes that contribute to ZIKV pathogenesis, we evaluated ZIKV 147 infection in 21 CC lines ( Table 1) . Because Oas1b is well-known as a dominant restriction factor 148 of flavivirus infection in mice, both in conventional laboratory mouse lines and in CC lines (12, 21, 149 22), we focused our study on lines that carry non-functional Oas1b alleles, although some lines 150 with functional Oas1b alleles were included for comparison. To determine whether any CC lines 151 were susceptible to ZIKV disease, we infected 5-week-old mice from 13 CC lines (CC001, CC002, 152 CC003, CC006, CC011, CC013, CC019, CC024, CC040, CC042, CC051, CC059, and CC061) 153
with 1000 FFU of ZIKV (or diluent alone) by subcutaneous inoculation in the footpad. We 154 evaluated 3 ZIKV strains ( Table 2) with distinct virulence phenotypes in immunodeficient mice.
(2, 13). MR766 is the prototype ZIKV strain and has been passaged ~150 times through suckling 157 mouse brains, which could result in mouse-adaptive mutations (14-16). However, the MR766 158 variant used in these studies contains a 4 amino acid deletion ablating an N-linked glycosylation 159 site in the viral envelope protein, resulting in a virus that is less virulent in Ifnar1 -/mice compared 160 to H/PF/2013 (2, 17). Dakar-MA was generated by passaging a ZIKV strain isolated from 161 mosquitos in Senegal in the 1980s (Dakar 41525) serially in Rag1 -/mice, resulting in a virus with 162 enhanced pathogenesis in mice (4). Mice were weighed daily after infection, as weight loss is a 163 sign of ZIKV disease in immunocompromised mouse models and typically precedes lethality (2). 164
In contrast to IFN-deficient mice (and similar to WT C57Bl/6J mice) (2), none of the CC lines 165 tested lost weight following infection with any ZIKV strain (Figure 1) . Indeed, most lines exhibited 166 modest weight gain over the 14 day experiment, and the rate of weight gain was no slower in 167 infected mice than in mock-infected controls. None of the mice exhibited disease signs consistent 168 with those observed in IFN-deficient mice (e.g. hunching, ruffled fur, paralysis, or encephalitis). 169 CC051 and CC059 share more genetic similarities than average pairs of CC mice, so phenotypes 170 that differ between these two lines may be especially easy to map by quantitative trait locus (QTL) 171 analysis. Because 5-week-old CC059 mice exhibited slightly slower weight gain after ZIKV 172 infection compared to mock-infected mice, whereas ZIKV infection had no effect on the rate of 173 weight gain in CC051 mice, we tested ZIKV infection in weanlings of these 2 lines. We reasoned 174 that because 3-week-old mice gain weight at a faster rate than 5-week-old mice, they may reveal 175 phenotypes that are not evident in 5-week-old mice. However, while we found that 3-week-old 176 mice indeed gained weight at a faster rate than 5-week-old mice, there was no difference in the 177 rate of weight gain in mice infected with ZIKV Dakar-MA compared to mock-infected, for either 178 CC051 or CC059 (Figure 2) we infected 5-week-old mice from 5 CC lines (CC001, CC040, CC042, CC051, and CC059) with 194 ZIKV Dakar-MA or H/PF/2013 and measured viral RNA in serum at 1, 3, and 5 days dpi by qRT-196
PCR. After ZIKV Dakar-MA infection, low-level viremia (approximately 10 FFU equivalents of viral 197
RNA per mL of serum) was detected at 1 dpi but it was greatly diminished by 3dpi (Figure 3) . All 198 CC001, CC042, and CC051 mice exhibited detectable viremia at 1dpi, whereas viremia was 199 detected in only a subset of CC040 and CC059 mice. No viral RNA was detected in mice infected 200 with ZIKV H/PF/2013, though viremia was evaluated only at 3 dpi and only in CC042, CC051, and 201 CC059 mice. We next evaluated ZIKV viremia in adult CC mice (15-21 weeks old) infected with 202 ZIKV Dakar-MA. Similar to 5-week-old mice, adult mice exhibited approximately 10 FFU 203 equivalents of viral RNA per mL of serum at 1dpi, which diminished by 3dpi and was undetectable 204 by 5dpi (Figure 4) . Altogether, these results show that while some ZIKV replication does occur in 205 CC mice, the virus is cleared rapidly, consistent with the lack of disease signs observed in CC 206 mice. Importantly, we did not observe robust differences in viremia between CC lines, indicating 207 that this is not a suitable phenotype for QTL mapping studies. 208
209

Zika virus infection induces neutralizing antibodies in Collaborative Cross mice. Since 210
ZIKV produced only transient low-level viremia in CC mice, we tested whether this was sufficient 211 to elicit the production of neutralizing antibodies. We collected serum at 14dpi from 5 CC lines 212 (CC001, CC040, CC042, CC051, CC059) infected with ZIKV H/PF/2013 at 5 weeks of age. Heat- human primates and mice (7), but ZIKV disease also has been studied in guinea pigs, hamsters, 231 tree shrews, and swine (27) (28) (29) (30) (31) (32) (33) (34) (35) . Mice offer significant advantages in terms of cost, scale, speed, 232 and genetic tractability, enabling mechanistic studies that are not feasible in non-human primate 233 models. A significant disadvantage of mouse models is that ZIKV replicates poorly in 234 immunocompetent mice and thus does not exhibit the tissue tropism and disease phenotypes 235 characteristic of human infection. Mice lacking type I IFN production or responses succumb to 236 ZIKV infection and exhibit broad tissue tropism, implying that the innate antiviral response is a 237 key barrier to ZIKV replication and pathogenesis in mice (2, 36) . Mice lacking the IFN-αβ receptor (alone, or also lacking the IFN-γ receptor) have provided useful models for studying ZIKV disease 239 phenotypes including congenital infection, sexual transmission, and ocular infection, as well as 240 for evaluating candidate vaccines and antivirals (37-43). The restriction of ZIKV replication in mice 241 results in part from an inability of ZIKV NS5 to degrade murine STAT2 and therefore ZIKV cannot 242 inhibit IFN signaling in mice by the same mechanism used in human cells (5, 6) . However, NS5-243 mediated antagonism restricts antiviral signaling only in infected cells whereas these responses 244 are sustained in uninfected cells responding to paracrine IFN signaling. Thus, Stat2 -/mice 245 succumb to ZIKV infection, but transgenic mice expressing human STAT2 only exhibit disease in 246 the context of ZIKV strains with additional mouse-adaptive mutations (4, 44). In addition, the ZIKV 247 NS2B-NS3 protease targets human but not murine STING, resulting in sustained IFN production 248
and diminished viral replication in mouse cells (3). However, mice lacking STING were not more 249 susceptible to ZIKV than wild-type mice (2, 3), implying that STING is a contributing but not 250 dominant factor restricting ZIKV infection in mice. 251
252
Flavivirus resistance is one of the earliest examples of a genetic determinant of pathogen 253 susceptibility defined in mice. Over 80 years ago, flavivirus resistance was shown to be inherited 254 in a single gene autosomal dominant manner (22, 45, 46) , and more than 15 years ago the 255 resistance phenotype was mapped to the Oas1b gene (47, 48) . More recent studies used F1 256 hybrids of CC mice to define genetic determinants of WNV pathogenesis and found that the QTL 257 with the largest effect mapped to Oas1b (12, 49) . The antiviral activity of Oas1b restricts all 258 flaviviruses (>13 viruses tested) and appears to act exclusively against flaviviruses. Other 259 members of the Oas gene family restrict viral replication by sensing dsRNA and synthesizing the 260 second messenger 2'-5' oligoadenylate, which activates the cytoplasmic RNA degrading enzyme 261
RNaseL. However, Oas1b is not catalytically active and does not activate RNaseL (50). The 262 flavivirus restricting activity of Oas1b is cell intrinsic and restricts viral replication in a post-entry 263 manner, but its mechanism is unknown (50, 51) . OAS orthologs in other species also restrict viral 264 SARS coronavirus, and chikungunya virus (10, 11), because they exhibit unique phenotypes that 279 are not necessarily predicted from the 8 founder lines. Thus, we sought to determine whether CC 280 mice might provide a useful model system for ZIKV. We found that, although ZIKV viremia was 281 detectable at 1dpi, the amount of viral RNA detected in serum was very low and cleared rapidly, 282 and infected mice exhibited no signs of disease including weight loss. Based on these results, the 283 tested CC lines are unlikely to be useful as models of ZIKV disease or as tools to map host factors 284 that control ZIKV pathogenesis. This was true even of CC lines carrying non-functional alleles of 285
Oas1b, which would be expected to be the most susceptible to flavivirus infection (12). 286 287 It is possible that additional approaches could reveal experimentally useful ZIKV phenotypes in 288 CC mice. These could include administering virus by an intravenous, rather than subcutaneous 289 route, or infecting with a higher dose of virus, although the 1x10 5 FFU dose we used for infections 290 with ZIKV Dakar-MA is quite high. Another approach would be administering an IFNAR-blocking 291 monoclonal antibody (MAR1-5A3) prior to ZIKV infection. In C57Bl/6J mice, MAR1-5A3 treatment 292 results in elevated viremia and relevant clinical phenotypes such as transplacental transmission, 293 though it is not sufficient to produce weight loss or lethality. Furthermore, our study tested only a 294 subset of CC lines; additional lines not tested here may reveal more robust pathogenesis 295 phenotypes. The overall lack of disease in CC mice highlights the species-specific restriction 296 factors that limit ZIKV infection in mice. CC mice remain a valuable system for studying host 297 factors that control flavivirus pathogenesis, but are likely to be more revealing for flaviviruses that 298 are able to cause more robust infection in mice than ZIKV. 
